Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/cr0ph/staging.phastar.com/wp-includes/functions.php on line 6260
Parkinsons and Effective Data Management Approaches
Abstract burst of orange and blue light particles

Efficient Project Management for a Late-Stage Parkinson’s Disease Study 

1 minute read

Published: January 6th, 2026

Phastar partnered with a biotechnology sponsor to manage statistical and data management activities for a late-stage clinical study in Parkinson’s disease. The project involved distributed teams, complex neurosurgical procedures, and questionnaire-driven endpoints—all under tight budget oversight. 

Key Challenges: 

  • Global team coordination across multiple time zones 
  • Limited internal statistical and data management expertise 
  • Complex CRF design for neurosurgical injections and questionnaire-based endpoints 
  • Need for strict oversight and cost control 

Our Approach: 

  • Scheduled cross-time-zone meetings to maximize participation and maintain momentum 
  • Provided clear, proactive explanations to support sponsor understanding at each stage 
  • Conducted detailed multidisciplinary reviews of complex CRF pages 
  • Ensured strict adherence to the project timeline to minimize rework and control budget impact 

Outcome: 

The study progressed smoothly, earning strong praise from all stakeholders. The sponsor commended Phastar’s professionalism, attention to detail, and proactive approach, noting significant improvements in collaboration, clarity, and project efficiency. 

Complete the form below to read the full case study

Related articles

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

October 29th, 2026 1 minute read

Interim analyses and safety reviews play a critical role in clinical trial oversight, providing decision-makers with ...

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

July 20th, 2026 1 minute read

Designing a first-in-human study is challenging. Designing one for a novel reproductive therapy with limited prior da...

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

July 20th, 2026 1 minute read

Accelerating clinical development requires more than speed, it demands a careful balance between innovation, scientif...